Clinical Trials Logo
  1. Home
  2. Epistaxis
  3. NCT01314274

Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

Epistaxis Clinical Trial

Official title:
A Randomized Double Blind Placebo Controlled Trial of Intranasal Submucosal Bevacizumab in Hereditary Hemorrhagic Telangiectasia

Clinical Trial Summary

In a case series intranasal submucosal bevacizumab has been shown to reduce epistaxis in patients suffering from Hereditary Haemorrhagic Telangiectasia together with KTP Laser therapy. The aim of this study is to evaluate the effectiveness of submucosal intranasal bevacizumab compared to placebo in a randomized double blind trial setting.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01314274
Study type Interventional
Source Medical University of Vienna
Contact
Status Completed
Phase Phase 2
Start date March 2011
Completion date June 2013
View Details
See also
  Status Clinical Trial Phase
Completed NCT05334017 - Xylometazoline and Cocaine for Nasal Vasoconstriction Phase 4
Not yet recruiting NCT04519463 - The Effect of Local Anesthesia With Lidocaine During Insertion and Removal of Nasal Packing Early Phase 1
Recruiting NCT01886768 - Double Versus Single Pledget Nasal Anesthesia for Transnasal Endoscopy N/A
Recruiting NCT00390663 - A Prospective Randomised Controlled Trial of Management of Recurrent Nosebleeds in Children Phase 4
Suspended NCT04054687 - Intranasal TXA for Anterior Epistaxis in the Emergency Department Phase 2
Completed NCT02285634 - The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial. N/A
Completed NCT01485224 - Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia Phase 2
Completed NCT00793117 - The Effect of Packing in Post Operative Management of FESS Phase 4
Recruiting NCT06259292 - Comprehensive HHT Outcomes Registry of the United States (CHORUS)
Recruiting NCT03850964 - Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz) Phase 2/Phase 3
Recruiting NCT05281952 - Medico-economic Evaluation of Management Strategies for Severe Epistaxis N/A
Completed NCT03360045 - Comparing Effectiveness of Merocel and Packing With Tranexamic Acid in the Management of Anterior Epistaxis Phase 4
Completed NCT04279288 - The Roles of Hilotherapy in the Management of Epistaxis and Nasal Fractures N/A
Completed NCT03912051 - Assessment of Performance and Safety of an Asymmetric Balloon in the Treatment of Intranasal Bleeding Managed in an Emergency Setting N/A
Not yet recruiting NCT02677467 - Correlation Between Epistaxis and Cardiovascular Disease N/A
Terminated NCT01051427 - Control of Epistaxis With Surgiflo N/A
Completed NCT00863356 - Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis N/A
Recruiting NCT05269849 - Sirolimus for Nosebleeds in HHT Phase 2
Not yet recruiting NCT05343650 - NOVAPAK Nasal Packing in Shellfish Allergic Patients Phase 4
Not yet recruiting NCT02963129 - Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHT Phase 3